Facile Therapeutics

About This Project

Facile Therapeutics

Led by a veteran biopharma team, Facile Therapeutics is repurposing the orally bioavailable small molecule Ebselen to demonstrate that this molecule, already de-risked for human safety in late stage trials, will be effective in treating Clostridium difficile infection (CDI). Facile has shown Ebselen is effective in an animal model of CDI, and will bring it directly into a streamlined Phase 2 proof-of-concept trial in early 2019.

Evolution Devices

HotDesk Fall 2018

FE3D

HotDesk Fall 2018